Hepatocellular Carcinoma References

Last updated: 08 August 2024
  1. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-1022. doi: 10.1002/hep.24199. PMID: 21374666
  2. Chow PK, Choo SP, Ng DC, et al. National Cancer Centre Singapore Consensus guidelines for hepatocellular carcinoma. Liver Cancer. 2016 Apr;5(2):97-106. doi: 10.1159/000367759. PMID: 27386428
  3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. PMID: 29628281
  4. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908-943. doi: 10.1016/j.jhep.2011.12.001. PMID: 22424438
  5. Heimbach JK, Kulik LM, Finn RS, et al. American Association for the Study of Liver Diseases (AASLD) guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.
  6. National Comprehensive Cancer Network. Hepatobilliary cancers. Version 1.2018. NCCN. https://www.nccn.org/. Feb 2018.
  7. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. PMID: 28620797
  8. Verslype C, Rosmorduc O, ESMO Guidelilnes Working Group, et al. Hepatocellular carcinoma: ESMO–ESDO Clinical practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23(Suppl 7):vii41-vii48. doi: 10.1093/annonc/mds225. PMID: 22997453
  9. Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016 Mar;22(1):7-17. doi: 10.3350/cmh.2016.22.1.7. PMID: 27044761
  10. Cancer Research UK. BCLC staging system and the Child-Pugh system. Cancer Research UK. https://www.cancerresearchuk.org/. Jan 2019.
  11. Chen LT, Martinelli E, Cheng AL, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020 Mar;31(3):334–351. doi:10.1016/j.annonc.2019.12.001. PMID: 32067677
  12. He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer. 2017 Oct;36(1):83. doi: 10.1186/s40880-017-0251-2. PMID: 29061175
  13. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018 Aug;68(2):723–750. doi: 10.1002/hep.29913. PMID: 29624699
  14. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Version 4.2019. NCCN. https://www.nccn.org/. Dec 2019.
  15. Saeki I, Yamasaki T, Maeda M, et al. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol. 2018 Sep;10(9):571–584. doi: 10.4254/wjh.v10.i9.571. PMID: 30310535
  16. Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct;29(Suppl 4):iv238–iv255. doi: 10.1093/annonc/mdy308. PMID: 30285213
  17. Cheng AL, Qin S, Ikeda M, et al. IMBrave 150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol. 2019 Nov;30(Suppl 9):ix86-ix87.
  18. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Hepatobiliary cancers. Version 2.2020. NCCN. https://www.nccn.org/. 08 May 2020.
  19. Yau T, Kang YK, Kim TK, et al. Nivolumab (NIVO) + Ipilimumab (IPI) combination therapy in patients with advanced hepatocellular (aHCC): Results from CheckMate 040. J Clin Oncol. 2019 May;37(Suppl 15):4012-4012. doi:10.1200/JCO.2019.37.15_suppl.4012.
  20. Benson AB, D'Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021 May;19(5):541-565. doi: 10.6004/jnccn.2021.0022. PMID: 34030131
  21. ClinicalKey. Clinical overview: hepatocellular carcinoma. ClinicalKey. https://www.clinicalkey.com. 27 Nov 2019.
  22. Ferrante ND, Pillai A, Singal AG. Update on the diagnosis and treatment of hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2020 Oct;16(10):506-516. PMID: 34017223
  23. Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020 Dec;38(36):4317-4345. doi: 10.1200/JCO.20.02672. PMID: 33197225
  24. Mak D, Kramvis A. Epidemiology and aetiology of hepatocellular carcinoma in Sub-Saharan Africa. Hepatoma Res. 2021;7:39. http://dx.doi.org/10.20517/2394-5079.2021.15.
  25. Muthiah M, Chong CH, Lim SG. Liver disease in Singapore. Euroasian J Hepato-Gastroenterol. 2018;8(1):66-68.
  26. Stuart KE. Systemic treatment for advanced hepatocellular carcinoma. UpToDate. https://www.uptodate.com. 11 May 2021.
  27. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: hepatobiliary cancers. Version 3.2021. NCCN. https://www.nccn.org/. 15 Jun 2021.
  28. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Version 1.2022. NCCN. https://www.nccn.org/. Mar 2022.
  29. Vogel A, Martinelli E; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021 Jun;32(6):801-805. doi: 10.1016/j.annonc.2021.02.014. PMID: 33716105
  30. Cho Y, Kim BH, Park JW. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison. Clin Mol Hepatol. 2023 Apr;29(2):252-262. doi: 10.3350/cmh.2023.0099. Accessed 11 Nov 2023. PMID: 36907570
  31. ClinicalKey: Drug Information Provided by Gold Standard. [online] Elsevier, Inc. Tremelimumab. ClinicalKey. https://www.clinicalkey.com. 2023.
  32. Ducreux M, Abou-Alfa GK, Bekaii-Saab T, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open. 2023 Jun;8(3):101567. doi: 10.1016/j.esmoop.2023.101567. PMID: 37263081
  33. Lexicomp. Tremelimumab: Drug information. UpToDate. https://www.uptodate.com/. 2023.
  34. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Hepatocellular carcinoma. Version 2.2023. NCCN. https://www.nccn.org/.
  35. Seth I, Siu A, Hewitt L, et al. Clinical practice guidelines for the management of hepatocellular carcinoma: A systematic review. J Gastrointest Cancer. 2023 Jul. doi: 10.1007/s12029-023-00961-0. PMID: 37480425
  36. U.S. Food & Drug Administration (US FDA). FDA approves Tremelimumab in combination with Durvalumab for unresectable hepatocellular carcinoma. US FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/. 18 Nov 2022. Accessed 06 Nov 2023.